Is there a benefit of re-induction therapy in adult patients with AML with <20% blasts?

Authors :: Paz Vellanki
Susan Lyerly
Leslie R. Ellis
Timothy S. Pardee
Sarah Dralle
Kavya Kannan
Heidi D. Klepin
Allison Winter
Bayard L. Powell
Bernard Tawfik
Dianna S. Howard
Megan Manuel
Scott Isom
Rupali Bhave
Source :: Journal of Clinical Oncology. 36:7021-7021
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 7021Background: Decision on re-induction (RI) therapy in adult patients with newly diagnosed acute myeloid leukemia (AML) who have received induction chemotherapy (ICT) when there are less than 20%...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Adult patients
business.industry
Induction chemotherapy
Myeloid leukemia
Newly diagnosed
hemic and lymphatic diseases
Internal medicine
Induction therapy
parasitic diseases
medicine
business

Full Text Access

Tools